Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
09/2000
09/28/2000WO2000056765A1 48 human secreted proteins
09/28/2000WO2000056760A1 Phenylalanine derivatives
09/28/2000WO2000056755A1 49 human secreted proteins
09/28/2000WO2000056754A1 48 human secreted proteins
09/28/2000WO2000056753A1 49 human secreted proteins
09/28/2000WO2000056751A1 50 human secreted proteins
09/28/2000WO2000056738A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000WO2000056729A1 Chemokine recpetor binding heterocyclic compounds
09/28/2000WO2000056728A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000WO2000056727A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000WO2000056725A1 N-adamant-1-yl-n'-[4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
09/28/2000WO2000056712A1 Sulfonamide derivatives as 5-ht7 receptor antagonists
09/28/2000WO2000056710A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors
09/28/2000WO2000056709A1 Indolinone compounds as kinase inhibitors
09/28/2000WO2000056704A1 Hydroxamic and carboxylic acid derivatives
09/28/2000WO2000056405A2 Human tumor necrosis factor receptor-like 2
09/28/2000WO2000056403A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
09/28/2000WO2000056363A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
09/28/2000WO2000056356A2 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000WO2000056353A2 A uro-genital condition treatment system
09/28/2000WO2000056350A2 Methods of use of beta 1-integrin inhibitors
09/28/2000WO2000056348A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000WO2000056346A1 Stable oil-in-glycerin emulsion
09/28/2000WO2000056341A1 Chemical compounds and their uses
09/28/2000WO2000056331A1 Inhibitors of impdh enzyme
09/28/2000WO2000056304A2 Anti-inflammatory uses of manzamines
09/28/2000WO2000056279A1 Resorcinol composition
09/28/2000WO2000056275A1 Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration
09/28/2000WO2000056153A1 Oral low dose butyrate compositions
09/28/2000WO2000041497A3 Use of apoptosis inducing agents in the treatment of (auto)immune diseases
09/28/2000WO2000039103B1 Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines
09/28/2000WO2000035428A3 Tricyclic nitrogen heterocycles as pde iv inhibitors
09/28/2000WO2000023114A3 Polymer conjugates of interferon beta- 1a and their uses
09/28/2000WO2000022143A3 Protein kinase homologs
09/28/2000WO2000022142A3 Cell signaling polypeptides and nucleic acids
09/28/2000WO2000020447A3 Polynucleotides coding for secreted polypeptides, some having similarity to syncollin or claudin or cytokine, their therapeutic uses
09/28/2000WO2000015793A3 Human gpcr proteins
09/28/2000WO2000013712A3 Methods and compositions for the prevention or treatment of cancer
09/28/2000DE19913731A1 Medizinische Zubereitung, enthaltend als Wirkstoff zumindest einen Anteil von Acetylsalicylsäure Medical preparation comprising as active ingredient at least a portion of acetylsalicylic acid
09/28/2000CA2855415A1 Phenylalanine derivatives
09/28/2000CA2368916A1 49 human secreted proteins
09/28/2000CA2368733A1 Phenylalanine derivatives
09/28/2000CA2368223A1 48 human secreted proteins
09/28/2000CA2368210A1 50 human secreted proteins
09/28/2000CA2368187A1 Upregulation of type iii endothelial cell nitric oxide synthase by hmg-coa reductase inhibitors
09/28/2000CA2368047A1 Chemokine receptor binding heterocyclic compounds
09/28/2000CA2368041A1 Indolinone compounds as kinase inhibitors
09/28/2000CA2367985A1 Tetrahydropyran derivatives and their use as therapeutic agents
09/28/2000CA2367963A1 Hydroxamic and carboxylic acid derivatives
09/28/2000CA2367866A1 Pyridine and pyrimidine derivatives and their use as inhibitors of cytokine mediated disease
09/28/2000CA2367699A1 Inflammatory mediation obtained from atractylodes lancea
09/28/2000CA2367620A1 47 human secreted proteins
09/28/2000CA2367488A1 Retroviral vectors comprising functional and non-functional splice donor and splice acceptor sites
09/28/2000CA2367132A1 Induction of antigen-specific unresponsiveness by glioblastoma culture supernatants (gcs)
09/28/2000CA2367118A1 A uro-genital condition treatment system
09/28/2000CA2367025A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist
09/28/2000CA2366877A1 Chemical compounds and their uses
09/28/2000CA2366691A1 48 human secreted proteins
09/28/2000CA2366650A1 Oral low dose butyrate compositions
09/28/2000CA2366267A1 49 human secreted proteins
09/28/2000CA2366132A1 48 human secreted proteins
09/28/2000CA2365405A1 Human tumor necrosis factor receptor-like 2
09/28/2000CA2365255A1 Human tumor necrosis factor receptor tr9
09/28/2000CA2365247A1 49 human secreted proteins
09/28/2000CA2365243A1 Human transmembrane proteins
09/28/2000CA2365238A1 48 human secreted proteins
09/28/2000CA2365223A1 46 human secreted proteins
09/28/2000CA2362705A1 N-adamant-1-yl-n'-¬4-chlorobenzothiazol-2-yl| urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
09/28/2000CA2361221A1 Novel protein which induces chondrocyte differentiation
09/27/2000EP1038962A1 Peptidoglycan biosynthetic gene murF from Streptococcus pneumoniae
09/27/2000EP1038872A1 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands
09/27/2000EP1038019A1 NOVEL ribB
09/27/2000EP1038011A2 Methods of producing anti-angiogenic proteins; endostatin, angiostatin or restin, using a pichia yeast expression system
09/27/2000EP1037994A1 Peptide antagonists of vascular endothelial growth factor
09/27/2000EP1037985A1 Restin and methods of use thereof
09/27/2000EP1037983A1 Mutants of endostatin, "em 1" having anti-angiogenic activity and methods of use thereof
09/27/2000EP1037981A1 Soluble inhibitors of vascular endothelial growth factor and use thereof
09/27/2000EP1037970A1 Secreted proteins and polynucleotides encoding them
09/27/2000EP1037887A1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
09/27/2000EP1037868A2 $g(a)-HYDROXY, -AMINO, AND HALO DERIVATIVES OF $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
09/27/2000EP1037661A1 ribH
09/27/2000EP1037655A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
09/27/2000EP1037653A1 Compositions and methods for regulating phagocytosis and icam-1 expression
09/27/2000EP1037651A1 Small peptides and methods for treatment of asthma and inflammation
09/27/2000EP1037648A2 The use of erythropoietin and iron preparations for producing pharmaceutical combination preparations for treating rheumatic diseases
09/27/2000EP1037639A1 Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
09/27/2000EP1037635A1 Compounds and methods
09/27/2000EP1037620A1 Use of formoterol in medicament for inflammation/allergy in upper airways
09/27/2000EP1037529A1 Composition useful for providing one-step surgical preparation and drape
09/27/2000EP1005351A4 An aqueous metal bicarbonate solution and method of use
09/27/2000EP0918792B1 Dipeptide benzamidine as a kininogenase inhibitor
09/27/2000EP0901465B1 Compounds with anti-inflammatory and immunosuppressive activities
09/27/2000EP0885188B1 Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
09/27/2000EP0848703B1 Derivatives of benzosulphonamides as inhibitors of the enzyme cyclo-oxygenase ii
09/27/2000EP0831889A4 Use of il-13 to induce 15-lipoxygenase
09/27/2000EP0777488A4 Composition and method for allogeneic mononuclear cell immunotherapy
09/27/2000CN1268138A Compounds
09/27/2000CN1268133A 2-Aminopyridines containing fused ring substituents as NOS inhibitors
09/27/2000CN1268122A Branched alkoxy- substituted 2-aminopyridines as NOS inhibitors
09/27/2000CN1268112A Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
1 ... 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 ... 1272